Abstract
Auraptene (AUR), a natural bioactive prenyloxy coumarin, is a highly
pleiotropic molecule that can bind to the MT1 receptor and can
effectively reduce the proliferation and migration of breast cancer
cells. Cisplatin (CDDP), as the first synthetic platinum-based
anticancer drug, is widely used in the clinic due to its definite
mechanism and therapeutic effect on diverse tumors. However, both of AUR
and CDDP exhibit some disadvantages when used alone, including poor
solubility, low bioavailability, lack of selectivity and systemic
toxicity when they are used singly.
Original language | English |
---|---|
Pages (from-to) | 8369-8382 |
Number of pages | 14 |
Journal | International Journal of Nanomedicine |
Volume | 2020 |
Issue number | 15 |
DOIs | |
Publication status | Published - 29 Oct 2020 |
Scopus Subject Areas
- Biophysics
- Bioengineering
- Biomaterials
- Pharmaceutical Science
- Drug Discovery
- Organic Chemistry
User-Defined Keywords
- Auraptene
- Cell imaging
- Cisplatin
- PH-responsive
- Tumor targeting